Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors



Status:Completed
Conditions:Breast Cancer, Lung Cancer, Lung Cancer, Prostate Cancer, Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/19/2018
Start Date:January 2014
End Date:December 2017

Use our guide to learn which trials are right for you!

Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.

This is a study to assess the safety of the combination of mifepristone and eribulin in
patients with metastatic or locally advanced unresectable breast or other specified solid
tumors, and determine preliminary efficacy of the combination of mifepristone and eribulin in
patients with metastatic or locally advanced unresectable Triple Negative Breast Cancer
(TNBC). The structure for the study is a single arm, non-randomized, open-label, multicenter
trial with no control group. The study will be conducted at up to 11 sites, with up to 40
evaluable patients

There will be two parts to the study: Part 1, a dose escalation phase, in which the MTD and
RP2D will be determined in up to 20 patients with metastatic breast or other specified solid
tumors, regardless of receptor status; and Part 2, a dose expansion phase in which a
preliminary estimate of efficacy will be made in an expansion group of up to 20 patients with
glucocorticoid receptor-positive metastatic TNBC at the RP2D.

Treatment will be administered in 21-day cycles, with the exception of the first cycle, which
will be of 28 days duration with a lead-in of 7 days dosing of mifepristone.

Cycle 1 (28-day cycle): Mifepristone administered orally (PO) with food once daily for 28
days. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on days 8 and 15.

Cycle 2 and beyond (21-day cycle): Mifepristone administered orally (PO) with food once daily
for 21 days. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on days 1
and 8.

Enrollment in Part 2 of the study (dose expansion) will occur once the RP2D has been
determined. Patients in the dose expansion study must have TNBC disease that is
glucocorticoid receptor-positive (by immunohistochemistry [IHC]). Patients will be treated in
repeated 21-day cycles until progression or another withdrawal criterion is met.

Part 1 of the study is complete. Part 2 of the study is ongoing.

Inclusion Criteria:

1. Informed consent given prior to study-specific screening procedures

2. ≥ 18 years old

Part 2, dose expansion:

1. Diagnosis of TNBC: < 1% cells positive for ER/progesterone receptor, and HER2 IHC
score of 0 or 1, or FISH HER2+ ratio of less than 1.8; patients with low ER IHC (> 1%
but < 10% cells positive), but negative by genomic assay are eligible

2. Inoperable metastatic or locally advanced unresectable disease

3. Patients should have received a minimum of one, and up to five prior chemotherapy
regimens

4. Must have submitted a diagnostic FFPE tumor tissue sample to confirm tumor GR
positivity. Tumor tissue may be from primary or metastatic lesion. In the absence of
sufficient tissue to complete IHC, a tumor biopsy will be required.

5. Tumor must be glucocorticoid receptor positive TNBC (≥10% positive cells by IHC of
tumor biopsy)

6. Must have measurable disease (RECIST v1.1) in at least one lesion not previously
irradiated unless documented evidence of progression

7. Patients with treated, stable brain metastases eligible providing treatment was ≥4
weeks prior to initiation of study drug, and baseline CT or MRI negative for new brain
metastases. Must not require therapy with corticosteroids.

8. ECOG performance status 0 or 1

9. Must have adequate bone marrow and renal/hepatic function at the screening visit (≤7
days preceding the lab assessment):

i. ANC ≥ 1,500/mm3, without G-CSF

ii. Platelets ≥ 100,000/mm3, without transfusion

iii. Hemoglobin ≥ 9 g/dL, without transfusion support

iv. AST or ALT ≤ 3 × ULN

v. Total serum bilirubin ≤ 1.5 times ULN

vi. Serum creatinine ≤ ULN

vii. Potassium and magnesium levels within normal limits. If below the lower limit of
normal, must have levels corrected by supplementation prior to starting study drug.

viii. albumin > 3.0 g/dL

10. PT/aPIT ≤ 1.5 x ULN

11. Disease-free period of > 3 years from any other previous malignancies, excluding
curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or
carcinoma in situ of the cervix.

12. Female patients of childbearing potential must have a negative serum pregnancy test.
Sexually active patients must be willing to use non-hormonal contraception, including
condom use by male partner, and barrier method by the female partner during the
treatment period and for at least 3 months after the last dose of the study drug.
Females considered not of childbearing potential include those who have been in
menopause > 2 years, or are surgically sterile (status post tubal ligation or
hysterectomy).

13. Must be able and willing to comply with the study visit schedule and study procedures.

14. Able to take oral medications

Exclusion Criteria:

1. Systemic cytotoxic therapies or radiotherapy ≤14 days prior to day 1 cycle 1

2. Major surgery within 4 weeks, or minor surgery within 2 weeks prior to day 1 of cycle
1

3. Endometrial bleeding

4. For two weeks prior to day 1 cycle 1, administration of specified cytochrome P450 3A
(CYP3A) inducers

5. Patients who are taking simvastatin or lovastatin. Patients should be switched to
alternative therapies a minimum of 2 weeks before starting study drug

6. Patients who have been treated with an investigational agent <21 days prior to day 1
of cycle 1

7. Concomitant use of biological agents including growth factors. Exception: 3- to
6-patient breast cancer cohort enrolled to explore the use of prophylactic
growth-factor support of a 1.4 mg/m2 dose of eribulin.

8. Patients who require treatment with systemic corticosteroids for serious medical
conditions or illnesses (e.g. immunosuppression after organ transplantation)

9. History of significant cardiac disease. Includes second/third degree heart block;
significant ischemic heart disease; mean QTc interval > 480 msec prior to study start;
poorly controlled hypertension; congestive heart failure of NYHA Class II or worse

10. Pregnant or breast-feeding

11. Any other significant co-morbid conditions that would impair study participation or
cooperation

12. In Part 2, unable or unwilling to consent to provision of tumor tissue for GR assay
We found this trial at
11
sites
Tucson, Arizona 85715
Principal Investigator: Manuel Modiano, MD
Phone: 520-290-2510
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Hyo Han, MD
Phone: 813-745-4933
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Principal Investigator: Elisavet Paplomata, MD
Phone: 404-686-8210
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Chicago, Illinois 60637
Principal Investigator: Rita Nanda, MD
Phone: 773-834-2756
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Carlos Becerra, MD
Phone: 214-370-1179
?
mi
from
Dallas, TX
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Principal Investigator: Neelima Denduluri, MD
Phone: 703-528-7303
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Kansas City, Missouri 64111
Principal Investigator: Timothy Pluard, MD
Phone: 816-932-6913
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
9280 W. Sunset Road Suite 100
Las Vegas, Nevada 89148
702.952.1251
Principal Investigator: Fadi Braiteh, MD
Phone: 702-952-3400
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Royal Oaks, Michigan 48073
?
mi
from
Royal Oaks, MI
Click here to add this to my saved trials
100 NE Loop 410; Suite 600
San Antonio, Texas 78216
210-424-1600
Principal Investigator: Sharon Wilks, MD
Phone: 210-637-0641
Cancer Care Centers of South Texas At Cancer Care Centers of South Texas, we are...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Tyler, Texas 75702
Principal Investigator: Donald Richards, MD
Phone: 903-579-9800
?
mi
from
Tyler, TX
Click here to add this to my saved trials